Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Inogen IncINGN · Entity 2083 | Chief Commercial Officer | February 27, 2026 | March 03, 2026 |
| VAPOTHERM INCVAPO · Entity 87270 | SVP & Chief Commercial Officer | January 02, 2023 | January 04, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Inogen Inc
Report date February 27, 2026 · Filed March 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 44,229 |
Ending reported balance
After 2026-03-01 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-03-01 · Exercise / conversion · Acquired 13,005 · Balance 50,251 Row 2 · 2026-03-01 · Tax withholding · Disposed 6,022 · Balance 44,229 F1: The reported shares were withheld to cover the Reporting Person's tax withholding liability in connection with a portion of a time-based restricted stock award that vested on March 1, 2026. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 20,000 |
Reported balance
After 2026-02-27 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-02-27 · Grant · Acquired 20,000 · Balance 20,000 F2: Each restricted stock unit represents a contingent right to receive one share of Inogen common stock. F3: Subject to the reporting person's continued service, 1/3rd of the restricted stock units shall vest on March 1, 2027 (the "2027 Vesting Commencement Date"), and 1/3rd of the restricted stock units shall vest every year thereafter on the same day of the year as the 2027 Vesting Commencement Date. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 26,010 |
Reported balance
After 2026-03-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-03-01 · Exercise / conversion · Acquired 13,005 · Balance 26,010 F2: Each restricted stock unit represents a contingent right to receive one share of Inogen common stock. F4: 1/3rd of the restricted stock units vested on March 1, 2026 (the "2026 Vesting Commencement Date"), and subject to the reporting person's continued service, 1/3rd of the restricted stock units shall vest every year thereafter on the same day of the year as the 2026 Vesting Commencement Date. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported shares were withheld to cover the Reporting Person's tax withholding liability in connection with a portion of a time-based restricted stock award that vested on March 1, 2026.
F2: Each restricted stock unit represents a contingent right to receive one share of Inogen common stock.
F3: Subject to the reporting person's continued service, 1/3rd of the restricted stock units shall vest on March 1, 2027 (the "2027 Vesting Commencement Date"), and 1/3rd of the restricted stock units shall vest every year thereafter on the same day of the year as the 2027 Vesting Commencement Date.
F4: 1/3rd of the restricted stock units vested on March 1, 2026 (the "2026 Vesting Commencement Date"), and subject to the reporting person's continued service, 1/3rd of the restricted stock units shall vest every year thereafter on the same day of the year as the 2026 Vesting Commencement Date.
VAPOTHERM INC
Report date January 02, 2023 · Filed January 04, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 88,434 |
Reported balance
After 2023-01-02 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-01-02 · Grant · Acquired 5,320 · Balance 88,434 F1: Restricted stock unit award granted under the Vapotherm, Inc. Amended and Restated 2018 Equity Incentive Plan (the "2018 Equity Plan") and the Vapotherm, Inc. Amended and Restated 2019 French Qualifying Sub Plan (the "French Sub Plan") in lieu of an annual increase in the reporting person's 2023 base salary. The restricted stock unit award will vest in full on December 31, 2023, subject to the reporting person's continued service as an employee or other service provider to the Issuer through the vesting date. F2: Includes 58,553 shares that will be issued over time upon vesting and settlement of restricted stock unit awards. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.70 · Expires 2033-01-02 | Direct | 54,675 |
Reported balance
After 2023-01-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-01-02 · Grant · Acquired 54,675 · Balance 54,675 F3: This option was granted under the 2018 Equity Plan and the French Sub Plan and will vest as to 25% of the underlying shares on January 2, 2024, and thereafter, as to the remaining 75% of underlying shares, in 36 monthly installments, subject to the reporting person's continued service as an employee or other service provider to the Issuer through the vesting dates. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock unit award granted under the Vapotherm, Inc. Amended and Restated 2018 Equity Incentive Plan (the "2018 Equity Plan") and the Vapotherm, Inc. Amended and Restated 2019 French Qualifying Sub Plan (the "French Sub Plan") in lieu of an annual increase in the reporting person's 2023 base salary. The restricted stock unit award will vest in full on December 31, 2023, subject to the reporting person's continued service as an employee or other service provider to the Issuer through the vesting date.
F2: Includes 58,553 shares that will be issued over time upon vesting and settlement of restricted stock unit awards.
F3: This option was granted under the 2018 Equity Plan and the French Sub Plan and will vest as to 25% of the underlying shares on January 2, 2024, and thereafter, as to the remaining 75% of underlying shares, in 36 monthly installments, subject to the reporting person's continued service as an employee or other service provider to the Issuer through the vesting dates.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 01, 2026 Filed Mar 3, 2026 21:58 UTC | Inogen Inc INGN · Entity 2083 | Exercise / conversionRestricted Stock Unit · Derivative | 13,005 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-088594 · ownership.xml · derivative · entry 4 Ramade Gregoire · CIK 0001752887 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,010 Underlying: Common Stock · 13,005 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Inogen common stock. F4 · derivative.exercise_date: 1/3rd of the restricted stock units vested on March 1, 2026 (the "2026 Vesting Commencement Date"), and subject to the reporting person's continued service, 1/3rd of the restricted stock units shall vest every year thereafter on the same day of the year as the 2026 Vesting Commencement Date. F4 · derivative.expiration_date: 1/3rd of the restricted stock units vested on March 1, 2026 (the "2026 Vesting Commencement Date"), and subject to the reporting person's continued service, 1/3rd of the restricted stock units shall vest every year thereafter on the same day of the year as the 2026 Vesting Commencement Date. Read SEC document |
| March 01, 2026 Filed Mar 3, 2026 21:58 UTC | Inogen Inc INGN · Entity 2083 | Tax withholdingCommon Stock | 6,022 | $6.10 | $36,734.20 |
DisclosureSEC source: 0001193125-26-088594 · ownership.xml · nonDerivative · entry 2 Ramade Gregoire · CIK 0001752887 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,229 F1 · shares: The reported shares were withheld to cover the Reporting Person's tax withholding liability in connection with a portion of a time-based restricted stock award that vested on March 1, 2026. Read SEC document |
| March 01, 2026 Filed Mar 3, 2026 21:58 UTC | Inogen Inc INGN · Entity 2083 | Exercise / conversionCommon Stock | 13,005 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-088594 · ownership.xml · nonDerivative · entry 1 Ramade Gregoire · CIK 0001752887 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,251 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 21:58 UTC | Inogen Inc INGN · Entity 2083 | GrantRestricted Stock Unit · Derivative | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-088594 · ownership.xml · derivative · entry 3 Ramade Gregoire · CIK 0001752887 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Inogen common stock. F3 · derivative.exercise_date: Subject to the reporting person's continued service, 1/3rd of the restricted stock units shall vest on March 1, 2027 (the "2027 Vesting Commencement Date"), and 1/3rd of the restricted stock units shall vest every year thereafter on the same day of the year as the 2027 Vesting Commencement Date. F3 · derivative.expiration_date: Subject to the reporting person's continued service, 1/3rd of the restricted stock units shall vest on March 1, 2027 (the "2027 Vesting Commencement Date"), and 1/3rd of the restricted stock units shall vest every year thereafter on the same day of the year as the 2027 Vesting Commencement Date. Read SEC document |
| December 01, 2025 Filed Dec 2, 2025 21:08 UTC | Inogen Inc INGN · Entity 2083 | Exercise / conversionRestricted Stock Unit · Derivative | 31,566 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-305257 · ownership.xml · derivative · entry 3 Ramade Gregoire · CIK 0001752887 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,565 Underlying: Common Stock · 31,566 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Inogen common stock. F3 · derivative.exercise_date: Subject to the reporting person's continued service, 1/3rd of the restricted stock units shall vest one year from December 1, 2023 (the "Vesting Commencement Date"), and 1/3rd of the restricted stock units shall vest every year thereafter on the same day of the year as the Vesting Commencement Date. F3 · derivative.expiration_date: Subject to the reporting person's continued service, 1/3rd of the restricted stock units shall vest one year from December 1, 2023 (the "Vesting Commencement Date"), and 1/3rd of the restricted stock units shall vest every year thereafter on the same day of the year as the Vesting Commencement Date. Read SEC document |
| December 01, 2025 Filed Dec 2, 2025 21:08 UTC | Inogen Inc INGN · Entity 2083 | Tax withholdingCommon Stock | 12,943 | $6.95 | $89,953.85 |
DisclosureSEC source: 0001193125-25-305257 · ownership.xml · nonDerivative · entry 2 Ramade Gregoire · CIK 0001752887 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,246 F1 · shares: The reported shares were withheld to cover the Reporting Person's tax withholding liability in connection with a portion of a time-based restricted stock award that vested on December 1, 2025. Read SEC document |
| December 01, 2025 Filed Dec 2, 2025 21:08 UTC | Inogen Inc INGN · Entity 2083 | Exercise / conversionCommon Stock | 31,566 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-305257 · ownership.xml · nonDerivative · entry 1 Ramade Gregoire · CIK 0001752887 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,189 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2025 Filed Mar 4, 2025 23:44 UTC | Inogen Inc INGN · Entity 2083 | GrantRestricted Stock Unit · Derivative | 39,015 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-032645 · ownership.xml · derivative · entry 1 Ramade Gregoire · CIK 0001752887 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,015 Underlying: Common Stock · 39,015 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Inogen common stock. F2 · derivative.exercise_date: Subject to the reporting person's continued service, 1/3rd of the restricted stock units shall vest on March 1, 2026 (the "Vesting Commencement Date"), and 1/3rd of the restricted stock units shall vest every year thereafter on the same day of the year as the Vesting Commencement Date. F2 · derivative.expiration_date: Subject to the reporting person's continued service, 1/3rd of the restricted stock units shall vest on March 1, 2026 (the "Vesting Commencement Date"), and 1/3rd of the restricted stock units shall vest every year thereafter on the same day of the year as the Vesting Commencement Date. Read SEC document |
| December 01, 2024 Filed Dec 3, 2024 22:05 UTC | Inogen Inc INGN · Entity 2083 | Exercise / conversionRestricted Stock Unit · Derivative | 31,565 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-132856 · ownership.xml · derivative · entry 3 Ramade Gregoire · CIK 0001752887 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,131 Underlying: Common Stock · 31,565 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Inogen common stock. F3 · derivative.exercise_date: Subject to the reporting person's continued service, 1/3rd of the restricted stock units shall vest one year from December 1, 2023 (the "Vesting Commencement Date"), and 1/3rd of the restricted stock units shall vest every year thereafter on the same day of the year as the Vesting Commencement Date. F3 · derivative.expiration_date: Subject to the reporting person's continued service, 1/3rd of the restricted stock units shall vest one year from December 1, 2023 (the "Vesting Commencement Date"), and 1/3rd of the restricted stock units shall vest every year thereafter on the same day of the year as the Vesting Commencement Date. Read SEC document |
| December 01, 2024 Filed Dec 3, 2024 22:05 UTC | Inogen Inc INGN · Entity 2083 | Tax withholdingCommon Stock | 12,942 | $9.71 | $125,666.82 |
DisclosureSEC source: 0000950170-24-132856 · ownership.xml · nonDerivative · entry 2 Ramade Gregoire · CIK 0001752887 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,623 F1 · shares: The reported shares were withheld to cover the Reporting Person's tax withholding liability in connection with a portion of a time-based restricted stock award that vested on December 1, 2024. Read SEC document |
| December 01, 2024 Filed Dec 3, 2024 22:05 UTC | Inogen Inc INGN · Entity 2083 | Exercise / conversionCommon Stock | 31,565 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-132856 · ownership.xml · nonDerivative · entry 1 Ramade Gregoire · CIK 0001752887 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,565 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 02, 2023 Filed Jan 4, 2023 17:49 UTC | VAPOTHERM INC VAPO · Entity 87270 | GrantStock Option (right to buy) · Derivative | 54,675 | $0.00 Strike: $2.70 | $0.00 |
DisclosureSEC source: 0001235802-23-000006 · primary_doc.xml · derivative · entry 2 Ramade Gregoire · CIK 0001752887 · SVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,675 Underlying: Common Stock · 54,675 shares Expires 2033-01-02 F3 · derivative.exercise_date: This option was granted under the 2018 Equity Plan and the French Sub Plan and will vest as to 25% of the underlying shares on January 2, 2024, and thereafter, as to the remaining 75% of underlying shares, in 36 monthly installments, subject to the reporting person's continued service as an employee or other service provider to the Issuer through the vesting dates. Read SEC document |
| January 02, 2023 Filed Jan 4, 2023 17:49 UTC | VAPOTHERM INC VAPO · Entity 87270 | GrantCommon Stock | 5,320 | $2.70 | $14,364.00 |
DisclosureSEC source: 0001235802-23-000006 · primary_doc.xml · nonDerivative · entry 1 Ramade Gregoire · CIK 0001752887 · SVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,434 F1 · shares: Restricted stock unit award granted under the Vapotherm, Inc. Amended and Restated 2018 Equity Incentive Plan (the "2018 Equity Plan") and the Vapotherm, Inc. Amended and Restated 2019 French Qualifying Sub Plan (the "French Sub Plan") in lieu of an annual increase in the reporting person's 2023 base salary. The restricted stock unit award will vest in full on December 31, 2023, subject to the reporting person's continued service as an employee or other service provider to the Issuer through the vesting date. F1 · price: Restricted stock unit award granted under the Vapotherm, Inc. Amended and Restated 2018 Equity Incentive Plan (the "2018 Equity Plan") and the Vapotherm, Inc. Amended and Restated 2019 French Qualifying Sub Plan (the "French Sub Plan") in lieu of an annual increase in the reporting person's 2023 base salary. The restricted stock unit award will vest in full on December 31, 2023, subject to the reporting person's continued service as an employee or other service provider to the Issuer through the vesting date. F2 · balance_after: Includes 58,553 shares that will be issued over time upon vesting and settlement of restricted stock unit awards. Read SEC document |
| November 15, 2022 Filed Nov 17, 2022 16:28 UTC | VAPOTHERM INC VAPO · Entity 87270 | PurchaseCommon Stock | 10,000 | $0.54 | $5,399.00 |
DisclosureSEC source: 0001235802-22-000123 · primary_doc.xml · nonDerivative · entry 1 Ramade Gregoire · CIK 0001752887 · SVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,114 F1 · balance_after: Includes 59,900 shares that will be issued over time upon vesting and settlement of restricted stock units granted under the Vapotherm, Inc. Amended and Restated 2018 Equity Plan and the Vapotherm, Inc. Amended and Restated 2019 French Qualifying Sub Plan. Read SEC document |
| November 07, 2022 Filed Nov 9, 2022 16:34 UTC | VAPOTHERM INC VAPO · Entity 87270 | GrantCommon Stock | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001235802-22-000118 · primary_doc.xml · nonDerivative · entry 1 Ramade Gregoire · CIK 0001752887 · SVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,114 F1 · shares: This award was granted under the Vapotherm, Inc. Amended and Restated 2018 Equity Incentive Plan (as amended from time to time, the "2018 Equity Plan") in the form of restricted stock units. The restricted stock units vest with respect to approximately one-third of the underlying shares on each of the one-year, two-year and three-year anniversaries of the grant date, subject to the Reporting Person's continued service as an employee or other service provider to the Issuer through the vesting dates. F2 · balance_after: Includes 59,900 shares that will be issued over time upon vesting and settlement of restricted stock units granted under the 2018 Equity Plan and the Vapotherm, Inc. Amended and Restated 2019 French Qualifying Sub Plan. Read SEC document |
| May 10, 2022 Filed May 12, 2022 21:30 UTC | VAPOTHERM INC VAPO · Entity 87270 | GrantStock Option (right to buy) · Derivative | 53,000 | $0.00 Strike: $3.16 | $0.00 |
DisclosureSEC source: 0001235802-22-000064 · primary_doc.xml · derivative · entry 2 Ramade Gregoire · CIK 0001752887 · SVP and Chief Comm Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,000 Underlying: Common Stock · 53,000 shares Expires 2032-05-10 F2 · derivative.exercise_date: This option was granted under the 2018 Equity Plan and the French Sub Plan and will vest as to 25% of the underlying shares on January 1, 2024, and thereafter, as to the remaining 75% of underlying shares, in 36 monthly installments, subject to the reporting person's continued service as an employee or other service provider to the Issuer through the vesting dates. Read SEC document |
| January 01, 2022 Filed Jan 4, 2022 16:49 UTC | VAPOTHERM INC VAPO · Entity 87270 | GrantOption to Purchase Common Stock · Derivative | 25,000 | $0.00 Strike: $20.71 | $0.00 |
DisclosureSEC source: 0001235802-22-000005 · primary_doc.xml · derivative · entry 2 Ramade Gregoire · CIK 0001752887 · SVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-01-01 F3 · derivative.exercise_date: This option was granted under the Vapotherm, Inc. Amended and Restated 2018 Equity Incentive Plan and the Vapotherm, Inc. Amended and Restated 2019 French Qualifying Sub Plan and will vest as to 25% of the underlying shares on January 1, 2023, and thereafter, as to the remaining 75% of underlying shares, in 36 monthly installments, subject to the Reporting Person's continued service as an employee or other service provider to the Issuer through the vesting dates. Read SEC document |
| January 01, 2022 Filed Jan 4, 2022 16:49 UTC | VAPOTHERM INC VAPO · Entity 87270 | GrantCommon Stock | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001235802-22-000005 · primary_doc.xml · nonDerivative · entry 1 Ramade Gregoire · CIK 0001752887 · SVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,114 F1 · shares: This award was granted under the Vapotherm, Inc. Amended and Restated 2018 Equity Incentive Plan and the Vapotherm, Inc. Amended and Restated 2019 French Qualifying Sub Plan in the form of restricted stock units. The restricted stock units vest with respect to approximately one-third of the underlying shares on each of the one-year, two-year and three-year anniversaries of the grant date, subject to the Reporting Person's continued service as an employee or other service provider to the Issuer through the vesting dates. F2 · balance_after: Includes 19,900 shares that will be issued over time upon vesting pursuant to restricted stock units granted under the Vapotherm, Inc. 2018 Equity Incentive Plan and the Vapotherm, Inc. Amended and Restated 2019 French Qualifying Sub Plan. Read SEC document |
| November 04, 2021 Filed Nov 5, 2021 16:35 UTC | VAPOTHERM INC VAPO · Entity 87270 | Exercise / conversionOption to Purchase Common Stock · Derivative | 2,000 | $0.00 Strike: $3.78 | $0.00 |
DisclosureSEC source: 0001790300-21-000014 · primary_doc.xml · derivative · entry 3 Ramade Gregoire · CIK 0001752887 · SVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,458 Underlying: Common Stock · 2,000 shares Expires 2028-07-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option is fully vested. Read SEC document |
| November 04, 2021 Filed Nov 5, 2021 16:35 UTC | VAPOTHERM INC VAPO · Entity 87270 | SaleCommon Stock | 2,000 | $25.03 | $50,060.00 |
DisclosureSEC source: 0001790300-21-000014 · primary_doc.xml · nonDerivative · entry 2 Ramade Gregoire · CIK 0001752887 · SVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,614 F1 · kind: These shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · balance_after: Includes 9,900 shares that will be issued over time upon vesting pursuant to restricted stock units granted under the Vapotherm, Inc. 2018 Equity Incentive Plan. Read SEC document |
| November 04, 2021 Filed Nov 5, 2021 16:35 UTC | VAPOTHERM INC VAPO · Entity 87270 | Exercise / conversionCommon Stock | 2,000 | $3.78 | $7,560.00 |
DisclosureSEC source: 0001790300-21-000014 · primary_doc.xml · nonDerivative · entry 1 Ramade Gregoire · CIK 0001752887 · SVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,614 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · balance_after: Includes 9,900 shares that will be issued over time upon vesting pursuant to restricted stock units granted under the Vapotherm, Inc. 2018 Equity Incentive Plan. Read SEC document |
| September 21, 2021 Filed Sep 22, 2021 16:51 UTC | VAPOTHERM INC VAPO · Entity 87270 | Exercise / conversionOption to Purchase Common Stock · Derivative | 2,000 | $0.00 Strike: $3.78 | $0.00 |
DisclosureSEC source: 0001235802-21-000121 · primary_doc.xml · derivative · entry 3 Ramade Gregoire · CIK 0001752887 · SVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,458 Underlying: Common Stock · 2,000 shares Expires 2028-07-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option is fully vested. Read SEC document |
| September 21, 2021 Filed Sep 22, 2021 16:51 UTC | VAPOTHERM INC VAPO · Entity 87270 | SaleCommon Stock | 2,000 | $27.48 | $54,960.00 |
DisclosureSEC source: 0001235802-21-000121 · primary_doc.xml · nonDerivative · entry 2 Ramade Gregoire · CIK 0001752887 · SVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,614 F2 · kind: These shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F1 · balance_after: Includes 9,900 shares that will be issued over time upon vesting pursuant to restricted stock units granted under the Vapotherm, Inc. 2018 Equity Incentive Plan. Read SEC document |
| September 21, 2021 Filed Sep 22, 2021 16:51 UTC | VAPOTHERM INC VAPO · Entity 87270 | Exercise / conversionCommon Stock | 2,000 | $3.78 | $7,560.00 |
DisclosureSEC source: 0001235802-21-000121 · primary_doc.xml · nonDerivative · entry 1 Ramade Gregoire · CIK 0001752887 · SVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,614 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 9,900 shares that will be issued over time upon vesting pursuant to restricted stock units granted under the Vapotherm, Inc. 2018 Equity Incentive Plan. Read SEC document |
| August 20, 2021 Filed Aug 23, 2021 16:16 UTC | VAPOTHERM INC VAPO · Entity 87270 | Exercise / conversionOption to Purchase Common Stock · Derivative | 2,000 | $0.00 Strike: $3.78 | $0.00 |
DisclosureSEC source: 0001235802-21-000110 · primary_doc.xml · derivative · entry 3 Ramade Gregoire · CIK 0001752887 · SVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,458 Underlying: Common Stock · 2,000 shares Expires 2028-07-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option is fully vested. Read SEC document |
| August 20, 2021 Filed Aug 23, 2021 16:16 UTC | VAPOTHERM INC VAPO · Entity 87270 | SaleCommon Stock | 2,000 | $25.31 | $50,620.00 |
DisclosureSEC source: 0001235802-21-000110 · primary_doc.xml · nonDerivative · entry 2 Ramade Gregoire · CIK 0001752887 · SVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,614 F1 · kind: These shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · balance_after: Includes 9,900 shares that will be issued over time upon vesting pursuant to restricted stock units granted under the Vapotherm, Inc. 2018 Equity Incentive Plan. Read SEC document |
| August 20, 2021 Filed Aug 23, 2021 16:16 UTC | VAPOTHERM INC VAPO · Entity 87270 | Exercise / conversionCommon Stock | 2,000 | $3.78 | $7,560.00 |
DisclosureSEC source: 0001235802-21-000110 · primary_doc.xml · nonDerivative · entry 1 Ramade Gregoire · CIK 0001752887 · SVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,614 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · balance_after: Includes 9,900 shares that will be issued over time upon vesting pursuant to restricted stock units granted under the Vapotherm, Inc. 2018 Equity Incentive Plan. Read SEC document |
| July 28, 2021 Filed Jul 29, 2021 16:26 UTC | VAPOTHERM INC VAPO · Entity 87270 | Exercise / conversionOption to Purchase Common Stock · Derivative | 8,000 | $0.00 Strike: $3.78 | $0.00 |
DisclosureSEC source: 0001235802-21-000090 · primary_doc.xml · derivative · entry 3 Ramade Gregoire · CIK 0001752887 · SVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,458 Underlying: Common Stock · 8,000 shares Expires 2028-07-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option is fully vested. Read SEC document |
| July 28, 2021 Filed Jul 29, 2021 16:26 UTC | VAPOTHERM INC VAPO · Entity 87270 | SaleCommon Stock | 8,000 | $25.00 | $200,000.00 |
DisclosureSEC source: 0001235802-21-000090 · primary_doc.xml · nonDerivative · entry 2 Ramade Gregoire · CIK 0001752887 · SVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,614 F1 · kind: These shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · balance_after: Includes 9,900 shares that will be issued over time upon vesting pursuant to restricted stock units granted under the Vapotherm, Inc. 2018 Equity Incentive Plan. Read SEC document |
| July 28, 2021 Filed Jul 29, 2021 16:26 UTC | VAPOTHERM INC VAPO · Entity 87270 | Exercise / conversionCommon Stock | 8,000 | $3.78 | $30,240.00 |
DisclosureSEC source: 0001235802-21-000090 · primary_doc.xml · nonDerivative · entry 1 Ramade Gregoire · CIK 0001752887 · SVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,614 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · balance_after: Includes 9,900 shares that will be issued over time upon vesting pursuant to restricted stock units granted under the Vapotherm, Inc. 2018 Equity Incentive Plan. Read SEC document |
| March 22, 2021 Filed Mar 23, 2021 16:06 UTC | VAPOTHERM INC VAPO · Entity 87270 | Exercise / conversionOption to purchase Common Stock · Derivative | 2,000 | $0.00 Strike: $3.78 | $0.00 |
DisclosureSEC source: 0001562180-21-002407 · primarydocument.xml · derivative · entry 3 Ramade Gregoire · CIK 0001752887 · SVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,458 Underlying: Common Stock · 2,000 shares Expires 2028-07-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option is fully vested. Read SEC document |
| March 22, 2021 Filed Mar 23, 2021 16:06 UTC | VAPOTHERM INC VAPO · Entity 87270 | SaleCommon Stock | 2,000 | $25.82 | $51,640.00 |
DisclosureSEC source: 0001562180-21-002407 · primarydocument.xml · nonDerivative · entry 2 Ramade Gregoire · CIK 0001752887 · SVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,614 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| March 22, 2021 Filed Mar 23, 2021 16:06 UTC | VAPOTHERM INC VAPO · Entity 87270 | Exercise / conversionCommon Stock | 2,000 | $3.78 | $7,560.00 |
DisclosureSEC source: 0001562180-21-002407 · primarydocument.xml · nonDerivative · entry 1 Ramade Gregoire · CIK 0001752887 · SVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,614 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 22, 2021 Filed Feb 22, 2021 16:09 UTC | VAPOTHERM INC VAPO · Entity 87270 | Exercise / conversionOption to purchase Common Stock · Derivative | 2,000 | $0.00 Strike: $3.78 | $0.00 |
DisclosureSEC source: 0001562180-21-001361 · primarydocument.xml · derivative · entry 3 Ramade Gregoire · CIK 0001752887 · SVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,458 Underlying: Common Stock · 2,000 shares Expires 2028-07-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option is fully vested. Read SEC document |
| February 22, 2021 Filed Feb 22, 2021 16:09 UTC | VAPOTHERM INC VAPO · Entity 87270 | SaleCommon Stock | 2,000 | $27.91 | $55,820.00 |
DisclosureSEC source: 0001562180-21-001361 · primarydocument.xml · nonDerivative · entry 2 Ramade Gregoire · CIK 0001752887 · SVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,614 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| February 22, 2021 Filed Feb 22, 2021 16:09 UTC | VAPOTHERM INC VAPO · Entity 87270 | Exercise / conversionCommon Stock | 2,000 | $3.78 | $7,560.00 |
DisclosureSEC source: 0001562180-21-001361 · primarydocument.xml · nonDerivative · entry 1 Ramade Gregoire · CIK 0001752887 · SVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,614 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 20, 2021 Filed Jan 20, 2021 16:10 UTC | VAPOTHERM INC VAPO · Entity 87270 | Exercise / conversionOption to purchase Common Stock · Derivative | 2,000 | $0.00 Strike: $3.78 | $0.00 |
DisclosureSEC source: 0001562180-21-000378 · primarydocument.xml · derivative · entry 3 Ramade Gregoire · CIK 0001752887 · SVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,458 Underlying: Common Stock · 2,000 shares Expires 2028-07-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option is fully vested. Read SEC document |
| January 20, 2021 Filed Jan 20, 2021 16:10 UTC | VAPOTHERM INC VAPO · Entity 87270 | SaleCommon Stock | 2,000 | $31.92 | $63,840.00 |
DisclosureSEC source: 0001562180-21-000378 · primarydocument.xml · nonDerivative · entry 2 Ramade Gregoire · CIK 0001752887 · SVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,614 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| January 20, 2021 Filed Jan 20, 2021 16:10 UTC | VAPOTHERM INC VAPO · Entity 87270 | Exercise / conversionCommon Stock | 2,000 | $3.78 | $7,560.00 |
DisclosureSEC source: 0001562180-21-000378 · primarydocument.xml · nonDerivative · entry 1 Ramade Gregoire · CIK 0001752887 · SVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,614 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 20, 2021 Filed Apr 27, 2021 16:37 UTC | VAPOTHERM INC VAPO · Entity 87270 | OtherEmployee Stock Option (right to buy) · Derivative | 11,375 | $0.00 Strike: $12.16 | $0.00 |
DisclosureSEC source: 0001235802-21-000024 · primary_doc.xml · derivative · entry 2 Ramade Gregoire · CIK 0001752887 · SVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,375 Underlying: Common Stock · 11,375 shares Expires 2030-01-01 F2 · kind: On January 1, 2020, the Reporting Person was granted a performance-based option under the Vapotherm, Inc. 2018 Equity Incentive Plan, the actual number of underlying shares of which was not ascertainable until determined by the Issuer's Compensation Committee after completion of the one-year performance period based on the Issuer's achievement of certain pre-determined performance goals for the year ended December 31, 2020. Once vested based on performance, the stock option would then be subject to additional time-based vesting. F3 · kind: On January 20, 2021, the Issuer's Compensation Committee determined based on 2020 performance that the performance goals were achieved at a 100% level, resulting in an option to purchase a total of 11,375 shares for the Reporting Person, with the first 25% tranche vesting on that day and the remaining 75% to vest in 36 nearly equal monthly installments thereafter, provided the Reporting Person continues to serve as an employee or other service provider to the Issuer through the applicable vesting date. F2 · derivative.exercise_date: On January 1, 2020, the Reporting Person was granted a performance-based option under the Vapotherm, Inc. 2018 Equity Incentive Plan, the actual number of underlying shares of which was not ascertainable until determined by the Issuer's Compensation Committee after completion of the one-year performance period based on the Issuer's achievement of certain pre-determined performance goals for the year ended December 31, 2020. Once vested based on performance, the stock option would then be subject to additional time-based vesting. F3 · derivative.exercise_date: On January 20, 2021, the Issuer's Compensation Committee determined based on 2020 performance that the performance goals were achieved at a 100% level, resulting in an option to purchase a total of 11,375 shares for the Reporting Person, with the first 25% tranche vesting on that day and the remaining 75% to vest in 36 nearly equal monthly installments thereafter, provided the Reporting Person continues to serve as an employee or other service provider to the Issuer through the applicable vesting date. Read SEC document |
| January 01, 2021 Filed Jan 5, 2021 16:10 UTC | VAPOTHERM INC VAPO · Entity 87270 | GrantStock Options (Right to buy) · Derivative | 15,000 | $0.00 Strike: $26.52 | $0.00 |
DisclosureSEC source: 0001562180-21-000084 · primarydocument.xml · derivative · entry 2 Ramade Gregoire · CIK 0001752887 · SVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-01-01 F2 · derivative.exercise_date: This option is eligible to vest as to 25% of the underlying shares on January 1, 2022 and thereafter, as to the remaining 75% of underlying shares, in 36 monthly installments, provided that the Reporting Person continues to serve as an employee or other service provider to the Issuer on each vesting date and otherwise subject to the Company's applicable equity incentive plan. Read SEC document |
| January 01, 2021 Filed Jan 5, 2021 16:10 UTC | VAPOTHERM INC VAPO · Entity 87270 | GrantCommon Stock | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-21-000084 · primarydocument.xml · nonDerivative · entry 1 Ramade Gregoire · CIK 0001752887 · SVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,614 F1 · shares: Represents restricted stock units ("RSUs") granted to the Reporting Person under the Issuer's equity incentive plan. Each RSU represents the contingent right to receive one share of Common Stock. The RSUs vest 100% on the third anniversary of the date of grant, subject to the Reporting Person's continuous service to the Issuer through such vesting date. Read SEC document |
| December 21, 2020 Filed Dec 21, 2020 16:03 UTC | VAPOTHERM INC VAPO · Entity 87270 | Exercise / conversionOption to purchase Common Stock · Derivative | 2,000 | $0.00 Strike: $3.78 | $0.00 |
DisclosureSEC source: 0001562180-20-007390 · primarydocument.xml · derivative · entry 3 Ramade Gregoire · CIK 0001752887 · Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,458 Underlying: Common Stock · 2,000 shares Expires 2028-07-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option is fully vested. Read SEC document |
| December 21, 2020 Filed Dec 21, 2020 16:03 UTC | VAPOTHERM INC VAPO · Entity 87270 | SaleCommon Stock | 2,000 | $27.65 | $55,300.00 |
DisclosureSEC source: 0001562180-20-007390 · primarydocument.xml · nonDerivative · entry 2 Ramade Gregoire · CIK 0001752887 · Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,114 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| December 21, 2020 Filed Dec 21, 2020 16:03 UTC | VAPOTHERM INC VAPO · Entity 87270 | Exercise / conversionCommon Stock | 2,000 | $3.78 | $7,560.00 |
DisclosureSEC source: 0001562180-20-007390 · primarydocument.xml · nonDerivative · entry 1 Ramade Gregoire · CIK 0001752887 · Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,114 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 20, 2020 Filed Nov 20, 2020 16:30 UTC | VAPOTHERM INC VAPO · Entity 87270 | Exercise / conversionOption to purchase Common Stock · Derivative | 2,000 | $0.00 Strike: $3.78 | $0.00 |
DisclosureSEC source: 0001562180-20-006820 · primarydocument.xml · derivative · entry 3 Ramade Gregoire · CIK 0001752887 · Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,458 Underlying: Common Stock · 2,000 shares Expires 2028-07-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option is fully vested. Read SEC document |
| November 20, 2020 Filed Nov 20, 2020 16:30 UTC | VAPOTHERM INC VAPO · Entity 87270 | SaleCommon Stock | 2,000 | $25.92 | $51,840.00 |
DisclosureSEC source: 0001562180-20-006820 · primarydocument.xml · nonDerivative · entry 2 Ramade Gregoire · CIK 0001752887 · Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,114 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| November 20, 2020 Filed Nov 20, 2020 16:30 UTC | VAPOTHERM INC VAPO · Entity 87270 | Exercise / conversionCommon Stock | 2,000 | $3.78 | $7,560.00 |
DisclosureSEC source: 0001562180-20-006820 · primarydocument.xml · nonDerivative · entry 1 Ramade Gregoire · CIK 0001752887 · Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,114 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 20, 2020 Filed Oct 22, 2020 16:02 UTC | VAPOTHERM INC VAPO · Entity 87270 | Exercise / conversionOption to purchase Common Stock · Derivative | 2,000 | $0.00 Strike: $3.78 | $0.00 |
DisclosureSEC source: 0001562180-20-006414 · primarydocument.xml · derivative · entry 3 Ramade Gregoire · CIK 0001752887 · Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,458 Underlying: Common Stock · 2,000 shares Expires 2028-07-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option is fully vested. Read SEC document |
| October 20, 2020 Filed Oct 22, 2020 16:02 UTC | VAPOTHERM INC VAPO · Entity 87270 | SaleCommon Stock | 2,000 | $30.62 | $61,240.00 |
DisclosureSEC source: 0001562180-20-006414 · primarydocument.xml · nonDerivative · entry 2 Ramade Gregoire · CIK 0001752887 · Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,114 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.